ES2473596T3 - Loci de inmunoglobulina humanizada - Google Patents

Loci de inmunoglobulina humanizada Download PDF

Info

Publication number
ES2473596T3
ES2473596T3 ES04778633.0T ES04778633T ES2473596T3 ES 2473596 T3 ES2473596 T3 ES 2473596T3 ES 04778633 T ES04778633 T ES 04778633T ES 2473596 T3 ES2473596 T3 ES 2473596T3
Authority
ES
Spain
Prior art keywords
spacer
human
humanized
locus
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04778633.0T
Other languages
English (en)
Spanish (es)
Inventor
Roland Buelow
Wim Van Schooten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therapeutic Human Polyclonals Inc
Original Assignee
Therapeutic Human Polyclonals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutic Human Polyclonals Inc filed Critical Therapeutic Human Polyclonals Inc
Application granted granted Critical
Publication of ES2473596T3 publication Critical patent/ES2473596T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES04778633.0T 2003-07-15 2004-07-15 Loci de inmunoglobulina humanizada Expired - Lifetime ES2473596T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48773303P 2003-07-15 2003-07-15
US487733P 2003-07-15
PCT/US2004/023226 WO2005007696A2 (en) 2003-07-15 2004-07-15 Humanized immunoglobulin loci

Publications (1)

Publication Number Publication Date
ES2473596T3 true ES2473596T3 (es) 2014-07-07

Family

ID=34079388

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04778633.0T Expired - Lifetime ES2473596T3 (es) 2003-07-15 2004-07-15 Loci de inmunoglobulina humanizada

Country Status (10)

Country Link
US (4) US7585668B2 (enExample)
EP (1) EP1644417B1 (enExample)
JP (2) JP2007537704A (enExample)
CN (2) CN1852925A (enExample)
AU (1) AU2004257292A1 (enExample)
CA (1) CA2532117C (enExample)
ES (1) ES2473596T3 (enExample)
IL (1) IL172885A0 (enExample)
MX (1) MXPA06000562A (enExample)
WO (1) WO2005007696A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1644417B1 (en) * 2003-07-15 2014-04-30 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
EP2029729A2 (en) * 2006-05-31 2009-03-04 Genzyme Corporation Methods of using anti-thymocyte globulin and related agents
ATE536374T1 (de) 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
US20090053210A1 (en) 2006-09-01 2009-02-26 Roland Buelow Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
EP2336329B8 (en) * 2007-06-01 2012-11-21 Omt, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenis human idiotype antibodies
EP2185692A4 (en) * 2007-08-10 2012-05-02 Medarex Inc HCO32 AND HCO27 AND RELATED EXAMPLES
CN101868144A (zh) * 2007-08-14 2010-10-20 奥瑞金治疗公司 具有失活的内源基因座的转基因鸡
EP2108696A1 (en) * 2008-04-10 2009-10-14 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Cis-acting diversification activator and method for selective diversification of nucleic acids
MX2011007660A (es) * 2008-12-18 2011-08-17 Kingdon Craig R Animales transgenicos no humanos que expresan anticuerpos humanizados y usos de los mismos.
PT2564695E (pt) * 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
CA2770825A1 (en) * 2009-08-13 2011-02-17 Crystal Bioscience Inc. Transgenic animal for production of antibodies having minimal cdrs
US8865462B2 (en) 2010-01-20 2014-10-21 Crystal Bioscience Inc. Sustained culture of avian gonocytes
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
CA2789154C (en) 2010-02-08 2024-06-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
ES2984483T3 (es) * 2010-03-31 2024-10-29 Ablexis Llc Ingeniería genética de ratones para la producción de anticuerpos quiméricos
ME03386B (me) 2010-06-22 2020-01-20 Regeneron Pharma Hibridni laki lanac imunoglobulina koji ispoljavaju miševi
RU2612903C2 (ru) 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
CN102250239B (zh) * 2011-06-13 2013-04-17 中国农业科学院哈尔滨兽医研究所 一种与兔出血症病毒vp60蛋白相结合的蛋白及其应用
RS66089B1 (sr) 2011-08-05 2024-11-29 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
EP3839049A3 (en) * 2011-09-19 2021-10-20 Kymab Limited Antibodies, variable domains & chains tailored for human use
RU2743589C2 (ru) 2011-10-17 2021-02-20 Регенерон Фармасьютикалс, Инк. Мыши с ограниченной тяжелой цепью иммуноглобулина
SI2793567T1 (sl) 2011-12-20 2019-05-31 Regeneron Pharmaceuticals, Inc. Humanizirane lahkoverižne miši
HK1200849A1 (en) 2011-12-22 2015-08-14 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
HRP20192218T1 (hr) * 2012-02-01 2020-03-06 Regeneron Pharmaceuticals, Inc. Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene
EP3348140B1 (en) 2012-03-16 2020-12-30 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
RU2018128915A (ru) 2012-03-16 2019-02-18 Регенерон Фармасьютикалз, Инк. ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К рН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ
JP2015519076A (ja) 2012-06-12 2015-07-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 限定された免疫グロブリン重鎖遺伝子座を有するヒト化非ヒト動物
KR102159163B1 (ko) 2012-08-03 2020-09-23 에스에이비, 엘엘씨 유전자삽입 동물에서 인간 항체의 제조를 위한 복합 염색체 조작
CN105734081A (zh) 2013-02-20 2016-07-06 瑞泽恩制药公司 具有修饰的免疫球蛋白重链序列的非人类动物
KR20150126863A (ko) * 2013-03-13 2015-11-13 리제너론 파마슈티칼스 인코포레이티드 공통 경쇄 마우스
EP2967013B1 (en) * 2013-03-13 2019-01-16 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
TW201532513A (zh) * 2014-01-10 2015-09-01 Alfur Fu-Hsin Hung 能產生比小鼠ＩgＥ量高出許多的人源化ＩgＥ之基因轉殖動物
EP3895528A1 (en) 2014-03-21 2021-10-20 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CN106164092A (zh) 2014-03-21 2016-11-23 瑞泽恩制药公司 表现不同结合特征的vl抗原结合蛋白
JP6721502B2 (ja) * 2014-05-02 2020-07-15 株式会社カイオム・バイオサイエンス ヒト抗体を産生する細胞
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
SG10202006332PA (en) * 2015-10-29 2020-08-28 Hoffmann La Roche Transgenic rabbit with common light chain
SMT202000558T1 (it) * 2016-11-04 2020-11-10 Regeneron Pharma Animali non umani aventi un locus di catena leggera di immunoglobulina lambda ingegnerizzata
US10879744B2 (en) 2016-12-05 2020-12-29 Koninklijke Philips N.V. Foreign object detection in a wireless power transfer system
EP3570668A1 (en) * 2017-01-19 2019-11-27 Open Monoclonal Technology, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
EP3731865A1 (en) 2017-12-29 2020-11-04 F. Hoffmann-La Roche AG Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
US20210000088A1 (en) * 2018-03-21 2021-01-07 Crystal Bioscience Inc. Transgenic chicken that produces human antibodies
JP7354306B2 (ja) 2019-06-27 2023-10-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
CN110540996B (zh) * 2019-08-29 2022-01-28 华中农业大学 一种克氏原螯虾i型溶菌酶gLysi2基因、其编码的gLysi2蛋白及其应用
WO2021127068A1 (en) * 2019-12-18 2021-06-24 Bristol-Myers Squibb Company Bcr transgenic mice with a common leader sequence
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
CN114854901B (zh) * 2022-06-22 2025-11-07 华南农业大学 与苦瓜全雌性状共分离的分子标记、引物及其应用
AU2024311339A1 (en) 2023-06-21 2026-01-08 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411881A (en) 1990-07-10 1995-05-02 Nkk Corporation Chicken-specific immunoglobulin G-producing hybridoma
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
AU7326796A (en) 1995-10-30 1997-05-22 Spectral Diagnostics Inc. Stable chicken b-cell line and method of use thereof
CA2362098C (en) 1999-02-05 2011-10-11 Jens-Ulrich Bulow Human polyclonal antibodies from genetically engineered animals
NZ516173A (en) 1999-06-04 2004-02-27 Tranxenogen Inc Methods for manipulating the avian genome
AU7491800A (en) 1999-09-15 2001-04-17 Therapeutic Human Polyclonals, Inc. Immunotherapy with substantially human polyclonal antibody preparations purifiedfrom genetically engineered birds
CA2422155A1 (en) * 2000-08-03 2002-02-14 Wim Van Schooten Production of humanized antibodies in transgenic animals
WO2004003157A2 (en) 2002-06-26 2004-01-08 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
EP1644417B1 (en) * 2003-07-15 2014-04-30 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
WO2006021962A2 (en) 2004-08-27 2006-03-02 Medic4All A.G System of medical information through mobile device
US20110077965A1 (en) 2009-09-25 2011-03-31 Cerner Innovation, Inc. Processing event information of various sources
US20120306653A1 (en) 2011-06-02 2012-12-06 Nokia Siemens Networks Oy Medical sensor
US20130021154A1 (en) 2011-07-21 2013-01-24 Solomon Clifford T Medical parameters notification system

Also Published As

Publication number Publication date
CA2532117A1 (en) 2005-01-27
JP2007537704A (ja) 2007-12-27
WO2005007696A3 (en) 2005-11-03
US20130189774A1 (en) 2013-07-25
CN103205436B (zh) 2016-05-25
CA2532117C (en) 2012-07-10
US8652842B2 (en) 2014-02-18
US20060026696A1 (en) 2006-02-02
EP1644417A2 (en) 2006-04-12
US7585668B2 (en) 2009-09-08
CN1852925A (zh) 2006-10-25
US8410333B2 (en) 2013-04-02
EP1644417B1 (en) 2014-04-30
US20100205682A1 (en) 2010-08-12
USRE47131E1 (en) 2018-11-20
AU2004257292A1 (en) 2005-01-27
CN103205436A (zh) 2013-07-17
IL172885A0 (en) 2006-06-11
JP2011182801A (ja) 2011-09-22
JP6017763B2 (ja) 2016-11-02
MXPA06000562A (es) 2006-03-30
WO2005007696A2 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
ES2473596T3 (es) Loci de inmunoglobulina humanizada
AU2001284703B2 (en) Production of humanized antibodies in transgenic animals
JP6705650B2 (ja) ヒトイディオタイプを有するげっ歯類抗体をコードするポリヌクレオチド及びそれを含む動物
US20050153392A1 (en) Transgenesis with humanized immunoglobulin loci
EP1690934A2 (en) Generation of xenogeneic antibodies
AU2001284703A1 (en) Production of humanized antibodies in transgenic animals
JP5188969B2 (ja) ヒト化免疫グロブリンを発現するトランスジェニック動物におけるｂ細胞アポトーシスの抑制
US20240373832A1 (en) Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
US20040158880A1 (en) Suppression of endogenous immunoglobulin expression in transgenic non-human animals expressing humanized or human antibodies
ZA200301723B (en) Production of humanized antibodies in transgenic animals.